Day: August 27, 2024

AS Inbank has issued 555,384 new shares through direct offering to existing shareholders and new investors. The subscription period ended on 23 August 2024 and the Supervisory Board of Inbank decided to issue a total of 10.14 million euros worth of new shares to 52 investors.  The subscription period took place from 9 August 2024 to 23 August 2024. The price of one offered share was 18.25 euros, of which 0.10 euros was the nominal value and 18.15 euros the share premium. As a result of the new share issue, Inbank’s share capital, after the registration of the share capital increase in the Estonian Commercial Register, will be 1,151,966.3 euros, and the total number of shares after the issue will be 11,519,663.  Priit Põldoja, Chairman of the Management Board, comments: “Inbank continues to operate successfully and grow even in challenging...

These data, published in The Journal for ImmunoTherapy of Cancer (JITC), demonstrate that TG6050 induces tumor regression and profound remodeling of the tumor microenvironment TG6050 has also shown to avoid toxicity associated with systemic administration of IL-12 and anti-CTLA-4 TG6050 is currently being evaluated in a Phase I clinical trial (Delivir) for non-small cell lung cancer Strasbourg (France), August 27, 2024, 7:30 am CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces the publication in the Journal for ImmunoTherapy of Cancer (JITC) of a peer-reviewed article which illustrates that TG6050 induces profound immune remodeling of the tumor microenvironment in animal models. The paper highlights TG6050’s potential to induce sustained...

H2TeessideAn illustrative image showing how bp’s proposed blue hydrogen facility on Teesside – H2Teesside – could look.H2Teesside is expected to be one of the UK’s largest low-carbon hydrogen production facilities – fully integrated with carbon capture technology. The project is targeting 1.2 GW of low-carbon hydrogen production, which equates to more than 10% of the UK’s 2030 hydrogen production target. It could capture and send for storage over two million tonnes of CO₂ per year, which is the equivalent to capturing the emissions from the heating of one million UK households. This project could also support economic development, jobs creation and regeneration of the Teesside region. Technip Energies and technology selection marks an important next step towards UK decarbonisation strategy.Technip Energies...

With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce treatment burden for people with paroxysmal nocturnal haemoglobinuria (PNH) in Europe and their caregivers Approval is based on COMMODORE 2, where subcutaneous (SC) PiaSky once a month was equivalent to intravenous eculizumab every two weeks1,2 PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration3Basel, 27 August 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved PiaSky® (crovalimab), a novel recycling monoclonal antibody that inhibits the complement protein C5, for adults and adolescents (12 years of age or older with a weight of 40 kg and above) with paroxysmal nocturnal haemoglobinuria (PNH) who are either new to, or have been previously...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 27, 2024 – Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, and Indivior PLC (NASDAQ/LSE: INDV) today announced the selection of clinical candidates from their GABAB positive allosteric modulator (PAM) research collaboration. Indivior has selected a compound for future development in substance use disorder and will now undertake all future development of their selected compound. Under the terms of the agreement, Addex is eligible for payment of up to USD 330 million on successful achievement of prespecified regulatory, clinical and commercial milestones as well as tiered royalties on the level of net sales from high single...

REGULATED INFORMATION   Unifiedpost continues its strategic focus on growing core digital services alongside portfolio rationalisation La Hulpe, Belgium – August 27, 2024, 7:00 a.m. CET – [REGULATED INFORMATION] Unifiedpost Group SA (Euronext: UPG) (Unifiedpost), a leading provider of integrated business communications solutions, presents its results for H1 2024. Digital Services revenue reported solid growth of 12,8% y/y, excluding the divestments of 21 Grams, FitekIN and ONEA. This is reflected in Unifiedpost’s growing customer base, which exceeded 1,3 million businesses at the end of H1 2024. Strategic & Operational HighlightsOn July 5, 2024, Unifiedpost signed an agreement to sell all shares of 21 Grams to PostNord Strålfors and formed a partnership. PostNord Strålfors will exclusively distribute Banqup in the Nordic countries...

Agreement further strengthens the long-term relationship between IBA and the University of Pennsylvania Louvain-La-Neuve, Belgium, August 27, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a Memorandum of Understanding with the University of Pennsylvania Health System for the installation of two Proteus®ONE1 compact proton therapy solutions at the Penn Presbyterian Medical Center in Philadelphia, PA, USA. The final contract is expected to be signed later this year. The University of Pennsylvania is a long-standing customer of IBA as well as a key partner in the development of ConformalFLASH®2, as the leading organization in the field of Flash irradiation with protons....

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 27, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the European Commission (EC) has extended the indications of the antifungal Cresemba® (isavuconazole) to pediatric patients and also granted an extension of market exclusivity by two additional years, which triggered a CHF 10 million milestone payment from Basilea’s license partner Pfizer Inc. Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “We are very pleased to have received the European Commission Decision to approve Cresemba for the use in children who suffer from invasive aspergillosis or mucormycosis. These severe mold infections primarily...

VANCOUVER, British Columbia, Aug. 26, 2024 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB US: DMGGF) (FRANKFURT: 6AX) (“DMG”), a vertically integrated blockchain and data center technology company, today announces its fiscal third quarter 2024 financial results. All financial references are in Canadian Dollars unless specified otherwise. Q3 2024 Financial Results HighlightsQ3 2024 revenue up 11% over the prior year to $8.3M, driven by self-mining revenues increasing 5% Net income of negative $3.8 million, a smaller loss versus the year-ago period 87 bitcoin mined in the third quarter, down from 152 bitcoin in the prior quarter, with a hashrate of 0.95 EH/s and fleet efficiency of 25.6 J/T Operating cash flow in the third quarter of -$1.3 million versus $4.5 million in the prior quarter Strong balance sheet...